NSAIDs: Risk of acute MI compared with remote use Unadjusted odds ratio Adjusted odds ratio 95% CI p Indomethacin 1.65 1.71 1.35-2.17 <0.0001 Sulindac 1.46 1.41 1.01-1.96 0.04 Meloxicam 1.34 1.37 1.05-1.78 0.02 Rofecoxib 1.32 1.22-1.42 Piroxicam 1.14 1.18 0.90-1.54 0.22 Other NSAIDs 1.22 0.94-1.46 0.15 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.
NSAIDs: Risk of acute MI compared with remote use Unadjusted odds ratio Adjusted odds ratio 95% CI p Ibuprofen 1.08 1.11 1.01-1.22 0.02 Celecoxib 1.09 1.02-1.15 0.008 Naproxen 1.03 0.95-1.22 0.22 Diclofenac 1.04 1.05 0.93-1.19 0.43 Valdecoxib 0.99 0.72-1.37 0.97 Ketoprofen 0.88 0.86 0.63-1.18 0.35 Nabumetone 0.83 0.60-1.14 0.26 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.
NSAID use in cohort study Drug use Patients Patient-years Percentage of cohort Celecoxib 299 550 220 201 46.04 Diclofenac 109 402 44 488 16.82 Ibuprofen 371 051 109 666 57.03 Indomethacin 40 168 9266 6.17 Ketoprofen 18 575 7577 2.86 Meloxicam 26 123 8413 4.02 Nabumetone 25 286 8368 3.89 Naproxen 172 295 51 645 26.48 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.
NSAID use in cohort study Drug use Patients Patient-years Percentage of cohort Other NSAIDs 90 539 32 832 13.92 Piroxicam 22 212 9243 3.41 Rofecoxib 209 974 112 760 32.27 Sulindac 15 906 6087 2.44 Valdecoxib 26 526 6161 4.08 Total 650 590 2 356 884.5 Aspirin 203 233 241 816 31.24 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.